ABSTRACT
Infection with Fasciola hepatica, a liver trematode, is not frequently reported in the United States. We describe 2 patients, both originally from Cape Verde, who illustrate the spectrum of clinical presentations of F. hepatica as well as the means of treating infection with this parasite. Patient 1 had extensive disease and underwent multiple diagnostic procedures before the correct diagnosis was reached. Patient 2, who had few symptoms, had fascioliasis diagnosed by a noninvasive evaluation. Both patients were treated with triclabendazole without experiencing significant side effects. Fascioliasis that has been imported to the United States may elude prompt or accurate diagnosis. Obtaining a detailed travel history and recognizing the clinical presentation early in the course of infection may permit timely and noninvasive identification of infection. Triclabendazole is now the recommended drug for treating for fascioliasis because of its efficacy, safety, and ease of use.
Subject(s)
Anthelmintics/therapeutic use , Benzimidazoles/therapeutic use , Fasciola hepatica , Fascioliasis/diagnosis , Fascioliasis/drug therapy , Travel , Adult , Africa, Western , Aged , Animals , Antibodies, Helminth/blood , Fasciola hepatica/immunology , Fasciola hepatica/isolation & purification , Fascioliasis/parasitology , Feces/parasitology , Humans , Male , Triclabendazole , United StatesABSTRACT
BACKGROUND: Nosocomial bloodstream infections (NBSIs) occur frequently in neonatal intensive care units (NICUs) and are associated with substantial morbidity and mortality. Little has been published regarding variation in NBSI among institutions. OBJECTIVE: To determine NBSI incidence among six NICUs and to explore how much variation is explained by patient characteristics and NICU practice patterns. METHODS: From October, 1994, to June, 1996, six regional NICUs prospectively abstracted clinical records of all neonates weighing <1,500 g. Occurrence of NBSI, defined as first positive culture occurring >48 h after admission, was analyzed in relation to baseline patient characteristics and several common therapeutic interventions. Variables significant in univariate analyses were analyzed by Cox proportional hazards regression. RESULTS: There were 258 NBSIs (incidence, 19.1%) among 1,354 inborn first admissions. Incidence varied significantly by site, from 8.5 to 42%. Birth weight, Broviac catheter use and parenteral nutrition were significantly associated with NBSI (P < 0.05). When controlling for these variables interinstitutional variation in NBSI occurrence decreased but remained significant. CONCLUSIONS: Neonatal NBSI incidence varies substantially among institutions despite adjustment for length of stay and some known risk factors. The uses of Broviac catheters and especially intravenous nutrition supplements were significant determinants of NBSI risk.
Subject(s)
Bacteremia/epidemiology , Blood-Borne Pathogens , Cross Infection/epidemiology , Intensive Care Units, Neonatal , Analysis of Variance , Bacteremia/diagnosis , Boston/epidemiology , Cohort Studies , Cross Infection/diagnosis , Female , Health Surveys , Humans , Incidence , Infant, Newborn , Infant, Very Low Birth Weight , Male , Proportional Hazards Models , Risk Assessment , Risk Factors , Survival RateABSTRACT
BACKGROUND: Nephrolithiasis may be an important consequence of indinavir therapy; however little has been published on the variation in incidence between different populations of patients or the possible mechanisms of calculus formation. OBJECTIVE: To examine variation in the incidence of indinavir-associated nephrolithiasis (IAN) in HIV-positive patients in relation to hemophilia and hepatitis C virus (HCV) infection. METHODS: Clinical data were abstracted retrospectively from the medical records of all adult patients treated with indinavir from September 1995 to September 1997. Occurrence of first IAN, defined as flank pain and hematuria after initiation of therapy, was analyzed in relation to hemophilia status and HCV infection. RESULTS: There were 17 episodes of IAN (22%) among 79 patients treated with indinavir. Of 10 patients with hemophilia, 50% developed IAN as compared with 17% of patients without hemophilia (P = 0.03). Median days to first IAN was 22 (range 7-110 days) for hemophiliacs and 156 (range 5-611 days) for those without hemophilia. Data for HCV status were available for 74 out of 79 patients: 10 out of 27 (37%) patients with HCV developed IAN compared with six out of 42 (14%) without HCV (P = 0.02). CONCLUSION: Overall incidence of IAN was higher than that previously reported and was significantly greater in hemophiliacs than in non-hemophiliacs. HCV may be a contributing factor.
Subject(s)
Anti-HIV Agents/adverse effects , HIV Infections/drug therapy , HIV Protease Inhibitors/adverse effects , Indinavir/adverse effects , Kidney Calculi/chemically induced , Adult , Female , HIV Infections/complications , Hemophilia A/complications , Hepatitis C/complications , Humans , Incidence , Kidney Calculi/epidemiology , Male , Risk FactorsABSTRACT
Two patients who required ventilatory support for acute pulmonary disease failed to be weaned when they developed the Guillain-Barré syndrome. Respiratory muscle weakness was a major sign of their acute neuromuscular disease because the manifestations of critical illness obscured the progressive paralysis. Both cases illustrate the difficulty in diagnosing acute neuromuscular syndromes in critically ill patients.
